CS2009's 3-in-1 Antibody Shows OS Edge Over PD-1+VEGF Combos at ASCO 2026

From a drug development standpoint, CStone has engineered what many in immuno-oncology have long sought: a way to harness CTLA-4 without triggering its infamous toxicity. The ASCO 2026 data show CS2009 not only minimizes VEGF-related side effects through a clever internalization mechanism but also opens the door to continuous CTLA-4 inhibition. This could redefine the OS ceiling for anti-PD-1 regimens and puts pressure on competitors still relying on cumbersome, toxic combination strategies.

At ASCO 2026, CStone presented clinical data for CS2009, a first-in-class trispecific antibody simultaneously targeting PD-1, VEGF, and CTLA-4. The results suggest the molecule has the potential to overcome longstanding limitations in immuno-oncology by offering deeper, more durable responses with a markedly improved safety profile. For the first time, a single agent addresses three immune-evasion pathways, potentially reshaping the standard of care for multiple tumor types.

“

At ASCO 2026, CStone presented clinical data for CS2009, a first-in-class trispecific antibody simultaneously targeting PD-1, VEGF, and CTLA-4.

The most striking findings center on tolerability. Historically, CTLA-4 inhibitors like ipilimumab have delivered survival benefits but at the cost of severe immune-related adverse events (irAEs) that often limit dosing to just two or three cycles. CS2009’s engineered CTLA-4 component is designed to avoid excessive activation of peripheral CTLA-4 single-positive T cells, with VEGF-mediated tumor enrichment further refining its effect. The ASCO data confirm that CTLA-4-related toxicities with CS2009 are notably lower than those of conventional CTLA-4 regimens, with irAE rates approaching levels typically seen with PD-1 monotherapy or PD-1-based bispecifics. This safety window enables continuous dosing, which is a critical differentiator: rather than halting treatment early, clinicians could potentially maintain CTLA-4 blockade over the full course of therapy, continuously priming new T-cell clones against emerging tumor antigens. Pharmacodynamic validation showed dose-dependent upregulation of ICOS, a recognized marker of T-cell activation, reinforcing the biological rationale.

On the VEGF side, a parallel challenge has been balancing efficacy with toxicity. Anti-VEGF therapies frequently cause hypertension and proteinuria, especially in older or frail populations. CS2009’s mechanism appears to reduce systemic VEGF-related toxicity by enriching within the tumor microenvironment and utilizing CTLA-4-mediated internalization to clear VEGF-antibody complexes, decreasing reflux into the peripheral circulation. This could be especially valuable in real-world patients who are often excluded from clinical trials due to comorbidities.

Perhaps most compelling for long-term outcomes is the suggestion of an overall survival (OS) benefit. While PD-1 plus VEGF combinations like atezolizumab-bevacizumab have consistently improved progression-free survival (PFS), a clear OS advantage has remained elusive. By incorporating CTLA-4, CS2009 aims to break through that ceiling. Early clinical activity was also observed in traditionally immunotherapy-insensitive “cold” tumors—those with low mutational burden and scant T-cell infiltration—highlighting the value of the trispecific mechanism in converting non-responders.

From a market perspective, CS2009 enters a competitive but fragmented landscape. PD-1/VEGF bispecifics such as ivonescimab are already in late-stage development, and next-gen CTLA-4 antibodies are being explored in combination, but no approved single agent combines all three mechanisms. If CStone’s data hold up in larger trials, CS2009 could become a backbone therapy, displacing current combinations and streamlining treatment regimens. The ability to administer a single infusion targeting three checkpoints simultaneously also promises reduced healthcare resource utilization compared to multi-drug protocols.